Pediatric Phase I Trial and Pharmacokinetic Study of MLN8237, an Investigational Oral Selective Small-Molecule Inhibitor of Aurora Kinase A: A Children's Oncology Group Phase I Consortium Study

PURPOSE: MLN8237, a selective small-molecule inhibitor of Aurora kinase A, has activity in a broad range of preclinical pediatric cancer models. We conducted a phase I trial in children with refractory/recurrent solid tumors to define the maximum-tolerated dose, toxicities, and pharmacokinetic prope...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: Mossé, Yael P., Lipsitz, Emily, Fox, Elizabeth, Teachey, David T., Maris, John M., Weigel, Brenda, Adamson, Peter C., Ingle, Mark A., Ahern, Charlotte H., Blaney, Susan M.
Format: Artigo
Jezik:Inglês
Izdano: 2012
Teme:
Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC4008248/
https://ncbi.nlm.nih.gov/pubmed/22988055
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-11-3251
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki